Augusto Vicario,Carlos D Martinez,Dolores Baretto et al.
Augusto Vicario et al.
Hypertension is a risk factor for mild cognitive deterioration and vascular dementia. Cognitive deterioration attributable to normal aging was distinguished from cognitive deterioration related to hypertension by means of neuropsychologic t...
Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients [0.03%]
基于血管紧张素受体阻滞剂的治疗在非裔美国人和白人患者中的降压疗效比较
George L Bakris,David Hg Smith,Thomas D Giles et al.
George L Bakris et al.
Blood pressure (BP) reductions with agents that block the renin-angiotensin system are regarded as less effective as monotherapy in African Americans than other ethnic groups. This practice-based study compares the efficacy of an angiotensi...
Randomized Controlled Trial
Journal of clinical hypertension (Greenwich, Conn.). 2005 Oct;7(10):587-95; quiz 596-7. DOI:10.1111/j.1524-6175.2005.04666.x 2005
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial [0.03%]
不同剂量厄贝沙坦氢氯噻嗪复方治疗单药控制不佳的高血压患者疗效和安全性——INCLUSIVE研究
Joel M Neutel,Elijah Saunders,George L Bakris et al.
Joel M Neutel et al.
This multicenter, prospective, open-label, single-arm study determined the efficacy and safety of irbesartan/hydrochlorothiazide (HCTZ) fixed combinations in patients (n=1005), aged 18 years and older, with uncontrolled systolic blood press...
Controlled Clinical Trial
Journal of clinical hypertension (Greenwich, Conn.). 2005 Oct;7(10):578-86. DOI:10.1111/j.1524-6175.2004.04720.x 2005
Domenic A Sica
Domenic A Sica
The angiotensin-converting enzyme (ACE) inhibitor drug class is one with considerable staying power. ACE inhibitors are not only well established antihypertensive agents but also are compounds that fairly regularly provide end-organ protect...
Your drug, my drug, or our drugs: how aggressive should we be with antihypertensive therapy? [0.03%]
您的药物，我的药物，还是我们的药物？我们应当对降压治疗采取多积极的态度？
Joseph L Izzo Jr
Joseph L Izzo Jr
In the prevention of hypertensive complications, especially stroke and kidney disease, "lower is better" because for each decrease of 20 mm Hg systolic or 10 mm Hg diastolic pressure in the population, cardiovascular risk is halved. Ideally...
Cardiovascular events in hypertension trials of Angiotensin-converting enzyme inhibitors [0.03%]
血管紧张素转换酶抑制剂抗高血压试验中心血管事件分析
William J Elliott
William J Elliott
Angiotensin-converting enzyme inhibitors are widely-prescribed drugs for hypertension and are supported by clinical trials in which they reduce cardiovascular events. In the high-risk patients in the Heart Outcomes Prevention Evaluation, th...
Analysis of recent papers in hypertension. An angiotensin receptor blocker is more effective than a calcium channel blocker in secondary stroke prevention [0.03%]
高血压近期研究论文分析。在二级卒中预防方面，血管紧张素受体阻滞剂比钙通道阻滞剂更有效
Michael J Bloch,Jan Basile
Michael J Bloch
Domenic A Sica
Domenic A Sica
On inspection of most treatment algorithms for hypertension, it is apparent that multiple drug classes are available. In choosing a medication class for hypertension therapy, nuances of the selection process often go unappreciated. This art...
Marvin Moser,Jan Basile,William Cushman
Marvin Moser
During the meeting of the American Society of Hypertension in San Francisco, CA on May 17, 2005, a roundtable was convened to discuss the relationship between hypertension, renal disease, and cardiovascular outcomes. Dr. Marvin Moser, Clini...